On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on Press Releases and More with NNW Prime! Click to View Details
TuesdayAug 01, 2017 12:32 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on August 1, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: DRYS 13.89% – News: Recent class action complaint reminder by law firm TST 11.26% – News: Expands corporate activism coverage with Activist Daily RAVE 10.48% – News: Launches new mobile app BLIN 9.35% – News: Chosen by commercial brokerage firm for marketing automation services CLRB 6.02% – News: Inks collaboration deal with Avicenna Oncology TRTC 5.69% – News: Posting Q2 2017 results on August 8 ETST 5.56% – News: Inks deal with CDBQ WKHS…

Continue Reading

TuesdayAug 01, 2017 12:08 pm

NetworkNewsBreaks – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) Enrolls First Patient in Phase 2b Trial of EGP-437 for Cataract Surgery

Shares of EyeGate Pharmaceuticals (NASDAQ: EYEG) are down 8% in mid-day trade. The specialty pharmaceutical company this morning said it has enrolled the first patient in the phase 2b clinical trial to evaluate its EyeGate® II Delivery System and EGP-437 combination product for the treatment of pain and inflammation in patients that have undergone cataract surgery with implantation of a monofocal posterior chamber IOL (intraocular lens). Top-line data is anticipated by year-end 2017. Under an exclusive worldwide licensing agreement signed with Valeant Pharmaceuticals International, Inc. (NYSE: VRX) earlier this year, a subsidiary of Valeant has commercial and manufacturing rights to…

Continue Reading

TuesdayAug 01, 2017 12:06 pm

NetworkNewsBreaks – Skyline Medical, Inc. (NASDAQ: SKLN) Inks Binding LOI for Merger Transaction with CytoBioscience

Skyline Medical (NASDAQ: SKLN) shares are up 4% this morning on news that the company has signed a binding letter of intent for a merger transaction with CytoBioscience, a privately held biomedical company. CytoBioscience is a creator and manufacturer of devices used in human cell research and is focused on new therapeutic drug development. CytoBioscience also has relationships with hospitals and government entities that it aims to leverage to open new markets for Skyline Medical’s STREAMWAY® System operating room safety products. “This is a great opportunity for both companies. The CytoBioscience group has a deep pipeline of projects and contracts…

Continue Reading

TuesdayAug 01, 2017 11:53 am

NetworkNewsBreaks – SinglePoint, Inc. (SING) Sees Continued Momentum with Plans to Develop Bitcoin Payment Solution

SinglePoint’s (OTC: SING) management team, in a recent audio press release, said the company is poised to make two to three additional acquisitions as SinglePoint sees further opportunity in the legal marijuana market and medical cannabis. The company is working to support cannabis dispensaries with an innovative cryptocurrency bitcoin solution and is also helping legal marijuana sellers create a solid online presence with its SingleSeed.com subsidiary. “The company’s recent online audio press release (http://nnw.fm/Kzrh2) illustrates how this Seattle-based full service mobile technology provider is transitioning into a diversified holding company. It is committed to growing in the cannabis industry. It…

Continue Reading

TuesdayAug 01, 2017 9:02 am

NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Adds Dr. Chuanhai Cao to Medical Research Team

India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced that Dr. Chuanhai Cao has joined its medical research team as a key advisor. “The addition of Dr. Cao will accelerate IGC’s efforts to move its Alzheimer’s product Hyalolex to clinical trials,” Ram Mukunda, CEO of IGC, noted in the news release. “Dr. Cao is a dynamic force in cannabis related therapies for Alzheimer’s disease. Dr. Cao has one co-inventor patent that has been approved for medical trials, and another patent that is currently being worked on for…

Continue Reading

MondayJul 31, 2017 1:00 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on July 31, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: NXTD 8.28% – News: Posts preliminary results for Q2, FH 2017 CELH 7.65% – News: Partnership with Qifeng Food Technology Co. Ltd. marks entrance into China market, nationwide distribution SNES 6.16% – News: City of Chicago commences pilot program utilizing SenesTech’s ContraPest EKSO 3.46% – News: Will report Q2 financial results on August 7 BIOL 3.30% – News: Will host Q2 financial results conference call on August 7 BWEN 1.87% – News: Appoints Jason…

Continue Reading

MondayJul 31, 2017 12:57 pm

NetworkNewsBreaks – China Internet Nationwide Financial Services, Inc. (NASDAQ: CIFS) Prices $20M Initial Public Offering

China Internet Nationwide Financial Services (NASDAQ: CIFS) this morning announced the pricing of its initial public offering of 2,023,146 of its ordinary shares at $10 per unit. The provider of financial advisory services to the underserved small-to-medium-sized enterprises (“SMEs”) market in China said its shares are expected to begin trading on the NASDAQ Global Market on August 8, 2017, under the symbol “CIFS.” FBR Capital Markets & Co. and B. Riley & Co., LLC are acting as joint book-running managers for the offering. The company has granted the underwriters a 45-day option to purchase up to 3,000,000 additional units at…

Continue Reading

MondayJul 31, 2017 12:16 pm

NetworkNewsBreaks – MagneGas Corp. (NASDAQ: MNGA) Reports Improvements in MagneGas2® Production; Shares at New 52-week Low

Shares of MagneGas (NASDAQ: MNGA) are down 4.8% mid-day, trading at a new 52-week low of $0.57. The company this morning reported a 150% improvement in MagneGas2® production rates and a 50% reduction in production costs since the introduction of Butanol as a feedstock in April 2017. “Operationally, the research, development and production of MagneGas2® is one of the largest contributors to our cost structure. The use of butanol positively impacts the Company's financial metrics in several ways. First, we are able to significantly reduce the labor hours required to produce our gas, which enables us to reallocate labor to…

Continue Reading

MondayJul 31, 2017 12:09 pm

NetworkNewsBreaks – InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) Updates on INSPIRE Study; Pulls from New 52-Week Low

Shares of InVivo Therapeutics (NASDAQ: NVIV) are down 27.5% mid-day, lifting off a new 52-week low of $1.70 set this morning. The company earlier today issued an update on the progress of its INSPIRE Study designed to demonstrate the safety and probable benefit of the Neuro-Spinal Scaffold™ for the treatment of complete thoracic spinal cord injury (SCI). InVivo reported overall patient improvements, as well as a temporary enrollment halt due to the death of a patient, unrelated to the company’s treatment. “The most recent patient to enroll into the INSPIRE study, who was implanted in late June 2017, passed away…

Continue Reading

MondayJul 31, 2017 12:04 pm

NetworkNewsBreaks – Mateon Therapeutics, Inc. (MATN) Shares Surge on Positive Initial Data from Phase 1b Study of OXi4503

Shares of Mateon Therapeutics (OTCQX: MATN) are up 26% this morning after the company released preliminary data from its phase 1b dose-ranging study of OXi4503 in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The data show that two of four patients achieved a complete remission after one cycle of treatment. Additionally, there were no dose-limiting toxicities observed in the fifth cohort and OXi4503 continued to have a favorable safety profile. “Every dose of OXi4503 tested in this study has shown encouraging signs of efficacy and a favorable safety profile, with the highest…

Continue Reading

Contact us: 212.418.1217